Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 3/20 | 0.44 |
| ▸ | ADH1C | P00326 | 2/20 | 0.42 |
| ▸ | PYGL | P06737 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7310148 | 0.90 | PYGL (0.43) | ADH1AADH1CPYGLL3MBTL1MEN1 | |
| SCHEMBL7340781 | 0.85 | L3MBTL1 (0.54) | ADH1AADH1CL3MBTL1MEN1KMT2A | |
| SCHEMBL11892724 | 0.83 | ADH1A (0.46) | ADH1AADH1CPYGLL3MBTL1MEN1 | |
| SCHEMBL4281691 | 0.79 | ADH1A (0.48) | ADH1AADH1CL3MBTL1MEN1KMT2A | |
| SCHEMBL9837028 | 0.79 | ADH1A (0.48) | ADH1AADH1CL3MBTL1MEN1KMT2A | |
| SCHEMBL8903152 | 0.78 | ADH1A (0.47) | ADH1AADH1CPYGLL3MBTL1MEN1 | |
| SCHEMBL27971919 | 0.78 | ADH1A (0.47) | ADH1AADH1CL3MBTL1MEN1KMT2A | |
| SCHEMBL8041770 | 0.78 | ADH1A (0.47) | ADH1AADH1CPYGLL3MBTL1MEN1 | |
| SCHEMBL13434155 | 0.77 | ADH1A (0.43) | ADH1AADH1CPYGLL3MBTL1MEN1 | |
| SCHEMBL11890381 | 0.77 | ADH1A (0.41) | ADH1AADH1CPYGLL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020128208-A1 | Nonpeptide agonists and antagonists of vasopressin receptors | EMORY UNIVERSITY | 2002-09-12 | — | — | US | disclosed |
| WO-2002047679-A2 | NONPEPTIDE AGONISTS AND ANTAGONISTS OF VASOPRESSIN RECEPTORS | EMORY UNIVERSITY (US) | 2002-06-20 | — | — | WO | disclosed |
| US-5864043-A | CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST | KARL THOMAE GMBH (DE) | 1999-01-26 | — | — | US | disclosed |
| US-5614519-A | (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists | KARL THOMAE GMBH (DE) | 1997-03-25 | — | — | US | disclosed |
| US-5602127-A | ADMINISTERING TO TREAT HYPERTENSION | KARL THOMAE GMBH (DE) | 1997-02-11 | — | — | US | disclosed |
| US-5594003-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-14 | — | — | US | disclosed |
| US-5591762-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
| EP-0392317-B1 | Benzimidazoles, drugs containing these compounds and process for their preparation | THOMAE GMBH DR K (DE) | 1996-01-03 | — | — | EP | disclosed |
| US-5459147-A | Angeotensin-antagonistic effects; hypotensive, antiischemic, and antidiabetic agents, treating glaucoma | DR. KARL THOMAE GMBH (DE) | 1995-10-17 | — | — | US | disclosed |
| EP-0581166-A1 | Benzimidazoles, process for their preparation and their use as angiotensin-II antagonists | Dr. Karl Thomae GmbH (DE) | 1994-02-02 | — | — | EP | disclosed |
| EP-0560330-A2 | Substituted benzimidazolyl derivatives, therapeutic agents containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1993-09-15 | — | — | EP | disclosed |
| EP-0556789-A2 | Substituted biphenyl derivatives, therapeutic agents containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1993-08-25 | — | — | EP | disclosed |
| EP-0502314-A1 | Benzimidazol, medicaments containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1992-09-09 | — | — | EP | disclosed |
| EP-0470543-A1 | Heterocyclic imidazoles, remedies containing them and processes for their preparation | Dr. Karl Thomae GmbH (DE) | 1992-02-12 | — | — | EP | disclosed |
| EP-0392317-A2 | Benzimidazoles, drugs containing these compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1990-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128208-A1 | Nonpeptide agonists and antagonists of vasopressin receptors | AVPR1A, AVPR2, AVPR1B | ADH1A 833/4885ADH1C 959/4885PYGL 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.